Clive Elliott Adams

Clive Elliott Adams

Auto-generated profile, based on publicly available information

Clive Elliott Adams

University of Nottingham, Nottingham, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 1998 in BMJ
Verified
Journal Article
Closed access
PDF file
BTBen Thornley
Ben Thornley
CAClive Adams
Clive Adams
Objective To provide a comprehensive survey of the content and quality of intervention studies relevant to the treatment of schizophrenia. Design Data were extracted from 2000 trials on the Cochrane Schizophrenia Group's register. Main outcome measures Type and date of publication, country of origin, language, size of study, treatment setting, participant group, interventions, outcomes, and quality of study. Results Hospital based drug trials undertaken in the United States were dominant in the sample (54%). Generally, studies were short (54%<6 weeks), small (mean number of patients 65), and poorly reported (64% had a quality score of ≤2 (maximum score 5)). Over 600 different interventions were studied in these trials, and 640 different rating scales were used to measure outcome. Conclusions Half a century of studies of limited quality, duration, and clinical utility leave much scope for well planned, conducted, and reported trials. The drug regulatory authorities should stipulate that the results of both explanatory and pragmatic trials are necessary before a compound is given a licence for everyday use.

19 May 2018 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
OGOn behalf of the founding members of the ICASR group
On behalf of the founding members of the ICASR group
EBElaine Beller
Elaine Beller
JCJustin Clark
Justin Clark
GTGuy Tsafnat
Guy Tsafnat
CAClive Adams
Clive Adams
PGPaul Glasziou
Paul Glasziou
Systematic reviews (SR) are vital to health care, but have become complicated and time-consuming, due to the rapid expansion of evidence to be synthesised. Fortunately, many tasks of systematic reviews have the potential to be automated or may be assisted by automation. Recent advances in natural language processing, text mining and machine learning have produced new algorithms that can accurately mimic human endeavour in systematic review activity, faster and more cheaply. Automation tools need to be able to work together, to exchange data and results. Therefore, we initiated the International Collaboration for the Automation of Systematic Reviews (ICASR), to successfully put all the parts of automation of systematic review production together. The first meeting was held in Vienna in October 2015. We established a set of principles to enable tools to be developed and integrated into toolkits. This paper sets out the principles devised at that meeting, which cover the need for improvement in efficiency of SR tasks, automation across the spectrum of SR tasks, continuous improvement, adherence to high quality standards, flexibility of use and combining components, the need for a collaboration and varied skills, the desire for open source, shared code and evaluation, and a requirement for replicability through rigorous and open evaluation. Automation has a great potential to improve the speed of systematic reviews. Considerable work is already being done on many of the steps involved in a review. The ‘Vienna Principles’ set out in this paper aim to guide a more coordinated effort which will allow the integration of work by separate teams and build on the experience, code and evaluations done by the many teams working across the globe.

20 April 2005 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
PTPrathap Tharyan
Prathap Tharyan
CAClive E Adams
Clive E Adams

3 December 2015 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
SMSuzanne M Murphy
Suzanne M Murphy
CIClaire B Irving
Claire B Irving
CAClive E Adams
Clive E Adams
MWMuhammad Waqar
Muhammad Waqar
A particularly difficult challenge for community treatment of people with serious mental illnesses is the delivery of an acceptable level of care during the acute phases of severe mental illness. Crisis-intervention models of care were developed as a possible solution. To review the effects of crisis-intervention models for anyone with serious mental illness experiencing an acute episode compared to the standard care they would normally receive. If possible, to compare the effects of mobile crisis teams visiting patients' homes with crisis units based in home-like residential houses. We searched the Cochrane Schizophrenia Group’s Study-Based Register of Trials. There is no language, time, document type, or publication status limitations for inclusion of records in the register. This search was undertaken in 1998 and then updated 2003, 2006, 2010 and September 29, 2014. We included all randomised controlled trials of crisis-intervention models versus standard care for people with severe mental illnesses that met our inclusion criteria. We independently extracted data from these trials and we estimated risk ratios (RR) or mean differences (MD), with 95% confidence intervals (CI). We assessed risk of bias for included studies and used GRADE to create a 'Summary of findings' table. The update search September 2014 found no further new studies for inclusion, the number of studies included in this review remains eight with a total of 1144 participants. Our main outcomes of interest are hospital use, global state, mental state, quality of life, participant satisfaction and family burden. With the exception of mental state, it was not possible to pool data for these outcomes. Crisis intervention may reduce repeat admissions to hospital (excluding index admissions) at six months (1 RCT, n = 369, RR 0.75 CI 0.50 to 1.13, high quality evidence), but does appear to reduce family burden (at six months: 1 RCT, n = 120, RR 0.34 CI 0.20 to 0.59, low quality evidence), improve mental state (Brief Psychiatric Rating Scale (BPRS) three months: 2 RCTs, n = 248, MD -4.03 CI -8.18 to 0.12, low quality evidence), and improve global state (Global Assessment Scale (GAS) 20 months; 1 RCT, n = 142, MD 5.70, -0.26 to 11.66, moderate quality evidence). Participants in the crisis-intervention group were more satisfied with their care 20 months after crisis (Client Satisfaction Questionnaire (CSQ-8): 1 RCT, n = 137, MD 5.40 CI 3.91 to 6.89, moderate quality evidence). However, quality of life scores at six months were similar between treatment groups (Manchester Short Assessment of quality of life (MANSA); 1 RCT, n = 226, MD -1.50 CI -5.15 to 2.15, low quality evidence). Favourable results for crisis intervention were also found for leaving the study early and family satisfaction. No differences in death rates were found. Some studies suggested crisis intervention to be more cost-effective than hospital care but all numerical data were either skewed or unusable. We identified no data on staff satisfaction, carer input, complications with medication or number of relapses. Care based on crisis-intervention principles, with or without an ongoing homecare package, appears to be a viable and acceptable way of treating people with serious mental illnesses. However only eight small studies with unclear blinding, reporting and attrition bias could be included and evidence for the main outcomes of interest is low to moderate quality. If this approach is to be widely implemented it would seem that more evaluative studies are still needed.

26 June 2019 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
LSLena Schmidt
Lena Schmidt
FSFarhad Shokraneh
Farhad Shokraneh
KSKirsten Steinhausen
Kirsten Steinhausen
CAClive E. Adams
Clive E. Adams
Much effort is made to ensure Cochrane reviews are based on reliably extracted data. There is a commitment to wide access to these data—for novel processing and/or reuse—but delivering this access is problematic. To describe a proof-of-concept programme to extract, curate and structure data from Cochrane reviews. One student of Applied Sciences (16 weeks full time), access to pre-publication review files and use of ‘Eclipse’ to create an open-access tool (RAPTOR) using the programming language Java. The final software batch processes hundreds of reviews in seconds, extracting all study data and automatically tidying and unifying presentation of data for return into the source review, reuse, or export for novel analyses. This software, despite being limited, illustrates how the efforts of reviewers meticulously extracting study data can be improved, disseminated and reused with little additional effort.

8 January 2007 in Trials
Verified
Journal Article
Open access
LSLaura Sheard
Laura Sheard
CAClive E Adams
Clive E Adams
NWNat Mj Wright
Nat Mj Wright
HEHany El-Sayeh
Hany El-Sayeh
RDRichard Dalton
Richard Dalton
CTCharlotte Ne Tompkins
Charlotte Ne Tompkins
In the United Kingdom (UK), there is an extensive market for the class 'A' drug heroin. Many heroin users spend time in prison. People addicted to heroin often require prescribed medication when attempting to cease their drug use. The most commonly used detoxification agents in UK prisons are buprenorphine, dihydrocodeine and methadone. However, national guidelines do not state a detoxification drug of choice. Indeed, there is a paucity of research evaluating the most effective treatment for opiate detoxification in prisons. This study seeks to address the paucity by evaluating routinely used interventions amongst drug using prisoners within UK prisons. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Pilot Study will use randomised controlled trial methodology to compare the open use of buprenorphine and dihydrocodeine for opiate detoxification, given in the context of routine care, within HMP Leeds. Prisoners who are eligible and give informed consent will be entered into the trial. The primary outcome measure will be abstinence status at five days post detoxification, as determined by a urine test. Secondary outcomes during the detoxification and then at one, three and six months post detoxification will be recorded.